SCHEMBL6166348

SCHEMBL6166348

O=C(Nc1cccc(Cl)c1C(=O)O)OCc1cc2cc(-c3ccccn3)ccc2o1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.40
ITGA5 P08648 1/20 0.40
HCAR2 Q8TDS4 1/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
MAPT P10636 1/20 0.37
MAOB P27338 1/20 0.37
P2RX7 Q99572 1/20 0.36
CASP3 P42574 1/20 0.36
PIM1 P11309 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
CNR1 P21554 1/20 0.35
ABL1 P00519 1/20 0.35
KDM4E B2RXH2 1/20 0.35
RORC P51449 1/20 0.35
NR1H4 Q96RI1 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6164343 0.90 PIM1 (0.49) ITGB1ITGA5MAOBCASP3PIM1
SCHEMBL6161802 0.84 PIM1 (0.36) ITGB1ITGA5MAOBCASP3PIM1
SCHEMBL6163992 0.84 PIM1 (0.49) NPC1RAB9AMAPTMAOBP2RX7
SCHEMBL6166009 0.84 PIM1 (0.37) ITGB1ITGA5MAOBCASP3PIM1
SCHEMBL6167618 0.84 MGLL (0.43) MAOBCASP3NR1H4
SCHEMBL6163345 0.74 CA12 (0.46) HCAR2NPC1RAB9AMAOB
SCHEMBL6164163 0.73 MAOB (0.43) MAPTMAOBKDM4ELMNA
SCHEMBL6166139 0.73 MGLL (0.43) HCAR2MAOB
SCHEMBL6162848 0.73 MGLL (0.43) MAOB
SCHEMBL6164433 0.73 MGLL (0.43) NPC1RAB9AMAOBCASP3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379516-B1 ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS HOFFMANN LA ROCHE (CH) 2005-11-16 EP disclosed
US-6903086-B2 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists SYNTEX (U.S.A.) LLC (US) 2005-06-07 US disclosed
EP-1379516-A1 ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-20020165235-A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists SYNTEX (U.S.A.) LLC 2002-11-07 US disclosed
WO-2002070500-A1 ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165235-A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists GPBAR1, GABRP, TBXA2R ITGB1 2424/4885ITGA5 2441/4885HCAR2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.